Green Subthreshold Laser Therapy for Chronic Central Serous Chorioretinopathy.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

12 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-01

Study Completion Date

2025-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic Central Serous Chorioretinopathy (CSCR) is a vision-threatening retinal disorder characterized by persistent subretinal fluid due to choroidal vascular hyperpermeability and retinal pigment epithelium (RPE) dysfunction. This study evaluates the efficacy and safety of green subthreshold laser therapy using Norlase µSec Technology as a novel, tissue-sparing approach for treating chronic CSCR. By targeting RPE repair without inducing visible retinal damage, this technique aims to resolve subretinal fluid, restore retinal architecture, and improve visual function. This is the first study to report clinical outcomes with this specific laser platform in chronic CSCR management.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy

NCT01327170

Central Serous Chorioretinopathy

COMPLETED NA

Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy

NCT04410861

Central Serous Chorioretinopathy

UNKNOWN NA

Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy

NCT05570591

Central Serous Chorioretinopathy

RECRUITING NA

Pseudo-PDT in Central Serous Chorioretinopathy

NCT02799992

Chronic Central Serous Chorioretinopathy

UNKNOWN NA

Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy

NCT01797861

Chronic Central Serous Chorioretinopathy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

the Presence of Subretinal Fluid (SRF)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

green subthreshold laser therapy

The intervention consists of green subthreshold laser therapy delivered using the Norlase µSec™ Technology, a novel microsecond-pulsed laser platform specifically designed for retinal treatments.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subretinal fluid for more than three months, confirmed by multimodal imaging, diagnosis of chronic CSC in at least one eye.

Exclusion Criteria

any evidence of choroidal neovascularization on multimodal imaging, as well as a history of previous photodynamic therapy (PDT) or focal laser treatment for CSC, prior diagnosis of ocular hypertension, glaucoma, and optic nerve disorders, presence of active retinal conditions such as vitreomacular traction, epiretinal membrane, diabetic retinopathy, or retinal vein occlusion, lens opacities that could interfere with retinal imaging or compromise visual acuity

Eligible Sex

ALL

Accepts Healthy Volunteers

No